Kyntra Bio, Inc.
kyntrabio.comWhat Do They Do?
Supplies roxadustat drug product to pharmaceutical partners and develops drug candidates for cancer and anemia patients.
10-K for FY2025, filed Mar 16, 2026We are developing FG-3246, a potential first-in-class antibody-drug conjugate (“ADC”) targeting CD46, for the treatment of metastatic…View ↗
We and our collaboration partners developed roxadustat (爱瑞卓®, EVRENZOTM), which is currently approved in Europe, Japan, the People’s…View ↗
Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas in support of pre-commercial…View ↗
How Do They Make Money?
Pharmaceutical partners pay for drug product when Kyntra delivers inventory; development collaborations can also bring upfront license fees, research reimbursements, milestone payments and royalties on product sales.
10-K for FY2025, filed Mar 16, 2026The transaction price for each collaboration agreement is determined based on the amount of consideration the Company expects to be…View ↗
Co-development billings resulting from the Company’s research and development efforts, which are reimbursable under its collaboration…View ↗
Milestone payments are also considered variable consideration, which requires the Company to make estimates of when achievement of a…View ↗
For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties…View ↗
Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas in support of pre-commercial…View ↗
-
10-K for FY2025, filed Mar 16, 2026
FY2025 revenue by product or service ↗
$6.4M
-
10-K for FY2025, filed Mar 16, 2026
$6.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Development and Other Revenue
|
9.2%
FY2022: 17%
|
Development and Other Revenue, FY2025
$592K Sources
|
|
|
Drug Product Revenue, Net
Sold outright
10-K for FY2025, filed Mar 16, 2026 |
91%
FY2022: 7.9%
|
Drug Product Revenue, Net, FY2025
$5.8M Sources
|
Sold outright |
Who Are Their Customers?
Astellas buys commercial-grade drug ingredients or bulk product for ongoing commercial activity in Europe and Japan.
10-K for FY2025, filed Mar 16, 2026Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas in support of pre-commercial…View ↗
Do Revenues Turn Into Profits?
Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$4.8M.
10-K for FY2025, filed Mar 16, 2026
−$45.9MView ↗
10-K for FY2025, filed Mar 16, 2026
$183.5MView ↗
10-K for FY2025, filed Mar 16, 2026
−$4.8MView ↗
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Aug 31, 2026
FibroGen Europe entered bankruptcy
Related obligations were settled for approximately $0.1 million.
Sources
8-K, filed Aug 31, 2026
As previously disclosed, the Company’s subsidiary, FibroGen Europe, voluntarily submitted for bankruptcy to the Finnish bankruptcy court in…View ↗
Shrinking. Revenue fell 97% in 4 years, from $235.3M in FY2021 to $6.4M in FY2025, about 59% a year.
Pipeline focus
The older report centers on pamrevlumab, with trials in lung disease, pancreatic cancer and muscular dystrophy; the latest centers on an antibody-drug conjugate for prostate cancer and roxadustat for lower-risk MDS.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 16, 2026
Roxadustat in China
The older report describes roxadustat as approved in China; the latest says the company sold its China operations, including its roxadustat assets, and retained rights in markets not held by AstraZeneca or licensed to Astellas.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 16, 2026
Loading...
